Compile Data Set for Download or QSAR
Report error Found 1048 Enz. Inhib. hit(s) with all data for entry = 9769
TargetTyrosine-protein kinase JAK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM277437(US10072026, Example 1-31 | US10947254, Example 1-3...)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/28/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM277437(US10072026, Example 1-31 | US10947254, Example 1-3...)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/28/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM277436(US10072026, Example 1-30 | US10947254, Example 1-3...)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/28/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM277641(US10072026, Example 6-60 | US10947254, Example 6-6...)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/28/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM277641(US10072026, Example 6-60 | US10947254, Example 6-6...)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/28/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM277640(US10072026, Example 6-59 | US10947254, Example 6-5...)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/28/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM277438(US10072026, Example 1-32 | US10947254, Example 1-3...)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/28/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM277587(US10072026, Example 6-6 | US10947254, Example 6-6 ...)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/28/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM277661(US10072026, Example 8-10 | US10947254, Example 8-1...)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/28/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM277661(US10072026, Example 8-10 | US10947254, Example 8-1...)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/28/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM277586(US10072026, Example 6-5 | US10947254, Example 6-5 ...)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/28/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM277585(US10072026, Example 6-4 | US10947254, Example 6-4 ...)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/28/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM277443(US10072026, Example 1-37 | US10947254, Example 1-3...)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/28/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM277527(US10072026, Example 4-18 | US10947254, Example 4-1...)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/28/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM277527(US10072026, Example 4-18 | US10947254, Example 4-1...)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/28/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM277590(US10072026, Example 6-9 | US10947254, Example 6-9 ...)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/28/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM277448(US10072026, Example 1-42 | US10947254, Example 1-4...)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/28/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM277525(US10072026, Example 4-16 | US10947254, Example 4-1...)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/28/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM487329(US10947254, Example 6-8 | US11780852, Example 6-8 ...)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/28/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM277447(US10072026, Example 1-41 | US10947254, Example 1-4...)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/28/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM277525(US10072026, Example 4-16 | US10947254, Example 4-1...)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/28/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM277531(US10072026, Example 4-22 | US10947254, Example 4-2...)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/28/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM277453(US10072026, Example 1-47 | US10947254, Example 1-4...)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/28/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM277668(US10072026, Example 8-17 | US10947254, Example 8-1...)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/28/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM277668(US10072026, Example 8-17 | US10947254, Example 8-1...)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/28/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM277529(US10072026, Example 4-20 | US10947254, Example 4-2...)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/28/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM277528(US10072026, Example 4-19 | US10947254, Example 4-1...)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/28/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM277528(US10072026, Example 4-19 | US10947254, Example 4-1...)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/28/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM277599(US10072026, Example 6-18 | US10947254, Example 6-1...)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/28/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM487211(US10947254, Example 1-51)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/28/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM277599(US10072026, Example 6-18 | US10947254, Example 6-1...)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/28/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM277456(US10072026, Example 1-50 | US10947254, Example 1-5...)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/28/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM277456(US10072026, Example 1-50 | US10947254, Example 1-5...)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/28/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM277455(US10072026, Example 1-49 | US10947254, Example 1-4...)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/28/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM277455(US10072026, Example 1-49 | US10947254, Example 1-4...)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/28/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM277532(US10072026, Example 4-23 | US10947254, Example 4-2...)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/28/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM277390(US10072026, Example 1 | 3-((1R,3s,5S)-3-((7-((5-me...)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/28/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM277454(US10072026, Example 1-48 | US10947254, Example 1-4...)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/28/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM277390(US10072026, Example 1 | 3-((1R,3s,5S)-3-((7-((5-me...)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/28/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM277454(US10072026, Example 1-48 | US10947254, Example 1-4...)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/28/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM277397(US10072026, Example 8 | N7-(5-methyl-1H-pyrazol-3-...)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/28/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM277397(US10072026, Example 8 | N7-(5-methyl-1H-pyrazol-3-...)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/28/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM277538(US10072026, Example 4-29 | US10947254, Example 4-2...)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/28/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM487214(US10947254, Example 1-54 | US11780852, Example 1-5...)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/28/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM277538(US10072026, Example 4-29 | US10947254, Example 4-2...)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/28/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM277396(US10072026, Example 7 | N5-((1R,3s,5S)-8-(ethylsul...)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/28/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM277536(US10072026, Example 4-27 | US10947254, Example 4-2...)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/28/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM277674(US10072026, Example 8-23 | US10947254, Example 8-2...)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/28/2021
Entry Details
US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM277400(US10072026, Example 11 | 1-(((1R,3s,5S)-3-((7-((5-...)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/28/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM277400(US10072026, Example 11 | 1-(((1R,3s,5S)-3-((7-((5-...)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/28/2021
Entry Details
US Patent

Displayed 1 to 50 (of 1048 total ) | Next | Last >>
Jump to: